Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
Latest Information Update: 01 Mar 2024
At a glance
- Drugs Ocrelizumab (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 25 Feb 2023 Results (n=22) assessing effect of ocrelizumab on Modulation of Meningeal Enhancement in Multiple Sclerosis presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Forum 2023
- 06 Oct 2022 Planned End Date changed from 1 Sep 2022 to 1 Mar 2023.
- 06 Oct 2022 Planned primary completion date changed from 1 Aug 2022 to 1 Mar 2023.